Aledade

Where named alternatives beat Aledade: a practice owner who wants capital up front or an exit gets it from aggregator acquirers — Oak Street Health under CVS, One Medical under Amazon — that buy practices outright, and agilon health advances deeper capital through full-risk, multi-payer contracts, while Aledade's savings-share economics pay only after a completed performance year (Forbes, Sep 6 2022; Hospitalogy, May 12 2022).

The cost of that gap is deal selection: owners prioritizing immediate liquidity or multi-payer full-risk upside are winnable by rivals, so Aledade's pitch is structurally back-loaded on demonstrated savings — which is why its February 2026 messaging stresses that practices now 'see savings in year one' rather than in the three to four years the industry historically took (Fierce Healthcare, Feb 9 2026).

Aledade leads the independent-practice value-based-care enablement cohort — Privia Health, agilon health, Pearl Health, and Vytalize Health are the named direct rivals (CB Insights; Hospitalogy, May 12 2022; Forbes, Sep 6 2022) — on MSSP scale: in 2024 it covered about 11% of MSSP beneficiaries and generated nearly 20% of program savings (Aledade, Sep 2 2025).

The decisive trade-offs are scope and economics: agilon health runs deeper full-risk, multi-payer arrangements with physician groups while Aledade stays MSSP-centered with practices keeping ownership; Privia operates a branded MSO model; and aggregator buyers — Oak Street Health under CVS, One Medical under Amazon — offer practices an outright sale rather than a savings-share partnership. The status-quo substitute the whole cohort displaces is remaining in fee-for-service; Aledade's 93%-versus-73% earn-rate gap in 2024 is its argument that the displacement works.

Demand shift is the driver: ACO enrollment grew 4.4% to 14.3 million Medicare beneficiaries in January 2026, MSSP added 35 ACOs to 511, and Aledade took roughly 1 in 5 new MSSP participants — the mainstream adoption co-founder Farzad Mostashari describes as replacing the early-adopter wave (CMS via Fierce Healthcare, Feb 9 2026). Practices can now see savings in year one, which management says shortened a three-to-four-year industry sales cycle.

Dated indicators to watch: 700+ organizations added for 2026 on top of 500+ for 2025; the Humana partnership expanded to rural clinics and FQHCs; the LEAD model (began January 1, 2026) as a potential new vector; and profitability — faster EBITDA growth planned for 2026 after $1 billion of 2025 revenue, supported by the December 2025 $500 million credit facility. A weakening indicator would be a slowdown in new MSSP applications — CMS approved 134 for 2026, including 72 new participants.

The category's movement strengthens Aledade's position against both fee-for-service incumbency and smaller enablement rivals. CMS reported 14.3 million Medicare beneficiaries enrolled in ACOs as of January 2026, up 4.4% from 13.7 million in 2025, with MSSP participation rising to 511 ACOs from 476, and Aledade serving roughly 1 in 5 new MSSP participants and nearly 20% of the total program in 2026 (CMS via Fierce Healthcare, Feb 9 2026).

Policy direction is supportive but not guaranteed: CMS Medicare director Chris Klomp has publicly said he wants to end 'unmanaged fee-for-service,' yet the ACO REACH model concludes at the end of 2026 with the 10-year LEAD model its successor from January 1, 2026, and CMS proposed flat Medicare Advantage rates for 2027 — transitions that could redirect or disrupt parts of the value-based revenue pool Aledade competes for (Fierce Healthcare, Feb 9 2026).

Thesis: Aledade is the default enablement partner for independent primary care entering value-based care — nearly 20% of MSSP savings on 11% of beneficiaries in 2024, $1 billion of revenue in 2025 with profitability, and category tailwinds of 4.4% ACO enrollment growth in January 2026 — and scale compounds because the EHR-agnostic playbook lowers onboarding cost with each cohort (Aledade newsroom, Sep 2 2025; Fierce Healthcare, Feb 9 2026).

Key risks against alternatives: a Medicare policy reversal or MSSP redesign, the ACO REACH wind-down at end-2026, and better-capitalized or deeper-risk rivals — agilon health's full-risk model, Privia's MSO, and aggregator acquirers offering practices cash at close. The thesis holds if MSSP and its LEAD successor keep expanding through 2027 and Aledade's practice-level savings keep beating the 73% program-wide earn rate; it breaks if a CMS redesign compresses shared-savings payments or the 2023-vintage $3.5 billion private valuation meets a repriced private market.

Aledade's thesis is most exposed to Medicare policy: its engine is the MSSP and the CMMI model portfolio, and CMS is ending the ACO REACH model at the end of 2026 while installing the LEAD model from January 1, 2026 — any retraction or redesign of these programs hits network revenue directly (Fierce Healthcare, Feb 9 2026). A CMS rule change that compresses shared-savings payments would flow through to the savings-share revenue model evidenced in 2024.

Observable mitigants: the LEAD model is a 10-year commitment and management expects it to add growth; by 2026 revenue spans MSSP, Medicare Advantage, Medicaid, and commercial contracts, diluting single-program concentration; and the December 2025 $500 million credit facility, expandable to $650 million, reduces near-term financing risk (Fierce Healthcare, Feb 9 2026). Execution risk is the onboarding pace itself — 700+ new organizations in one cycle — and, as a private company, Aledade publishes no filings, leaving concentration and counterparty detail on management statements.

Aledade's value capture rides on a share of the savings its practices earn rather than a published price list: in performance year 2024 the network earned more than $775 million in shared-savings payments — over $665 per beneficiary, up 20% year over year, and roughly $390,000 per practice — while returning more than $320 million to Medicare (Aledade newsroom, Sep 2 2025).

The company reached $1 billion in revenue in 2025 and was 'comfortably' profitable that year, targeting faster EBITDA growth in 2026, with a $500 million Ares-led credit facility (expandable to $650 million) doubling committed financing capacity in December 2025 (Fierce Healthcare, Feb 9 2026). The missing denominator is Aledade's own take rate: the split of that $775 million between practices and the company is not disclosed, so gross-to-net margins and capital intensity per practice cannot be computed from public sources.

Aledade sells independent primary care practices, clinics, and community health centers a value-based-care operating platform: the technology, regulatory, and financial infrastructure to earn shared-savings revenue through accountable care organizations, an alternative to selling the practice, joining a hospital system, or staying in fee-for-service. As of the 2026 program year its contracts span the Medicare Shared Savings Program, Medicare Advantage, Medicaid, and commercial programs. The packaging is a network of locally led ACOs rather than an employer or buyer of practices.

Delivery runs through software embedded in each practice's existing electronic health record workflow — Aledade does not force a system change — with AI and analytics surfacing at-risk patients at the point of care; management said in February 2026 that this platform let it onboard more than 700 new organizations for 2026 faster than ever. In the 2024 performance year the network operated 59 ACOs on behalf of more than 1,900 primary care organizations serving over 1 million Medicare beneficiaries (Aledade newsroom, Sep 2 2025).